Dr. Kenneth Blum (born August 8, 1939) is a researcher on neuropsychopharmacology and genetics. Dr. Kenneth Blum is known from his study on the genetics of alcoholism published in the Journal of the American Medical Association in 1990. Dr. Kenneth Blum works in the fields of neuropsychiatry and genetics, nutritional genetics, and pharmacogenetics. Blum's research has been recognized through numerous awards. Dr. Blum is currently an adjunct full professor in the Department of Psychiatry, University of Florida College of Medicine, and Mcknight Brain Institute (Gainesville, Florida), and formerly of the Department of Physiology & Pharmacology at Wake Forest University School of Medicine (Winston-Salem, North Carolina). Until 2008 he was also Chief Scientific Officer of Salugen, Inc., a personalized health and wellness company in San Diego, California. In 1995 Dr. Kenneth Blum retired as a full professor in the Department of Pharmacology, University of Texas, where he was also chief of the Division of Addictive Diseases, chief of the Division of Substance and Alcohol Misuse, and director of the Laboratory of Pharmacogenetics at the University of Texas Health Science Center (San Antonio, Texas). Currently Dr. Kenneth Blum is the Chairman of the Board and Chief Scientific Officer of LifeGen Inc. (San Diego, California), a neutrigenomic evidence-based corporation.

Dr. Kenneth Blum's research interest includes genetics of alcoholism, neuropsychiatry and genetics, nutritional genetics, and pharmacogenetics.

1. What makes an article top quality? 

Response: Sound data and thoughtful hypotheses.

2. Do you think that journals determine research trends?

Response: NO.

3. What makes a good position paper?

Response: Hot Topics and issues.

4. What are the qualities you look for in an article?

Response: Authorship, institution and clear message.

5. Can you give us a broad indication of the types of themes a scientific journal should cover?

Response: Neuroscience, Genomics, Addiction, Psychiatry, Biotechnology etc.

6. What sorts of research methods and frameworks do you expect people to use, and how will they balance conceptual and applied research?

Response: Sound statistical analyses and novel neuroimaging for brain research.

7. How would you describe the journal’s mission and editorial objectives to our readers?

Response: Clear with focus.

8. If you could be granted dream articles, what would they be on?

Response: Addiction research and Therapy and genomic solutions using Systems Biology.

9. Are there any particular areas which you would like to see, or expect to see, collaborate?

Response: Neuropsychiatric Genetics.

10. How does the research published percolate through to practitioners?

Response: Need press release and media attention.

11. How can a publisher ensure the authors/readers a rigorous peer review and quality control?

Response: Using good peer scientists that are fair and without bias.

12. Your editorial policy is to be eclectic and welcome perspectives from other disciplines and schools. How does this translate into the types of contributions you encourage?

Response: Encourage many different disciplines from many countries.

13. What do you see as the merits of journals, as opposed to book series, as a means of scholarly communications?

Response: Need PUBMED or else Journal will fail.

14. How do you differentiate Journal of Genetic Disorders and Genetic Reports Research with other journals in the field?

Response: Do not know except for seeking good papers and highly indexed or doomed.